Gastroparesis Patients: Disease Impact and Medication Risk Assessment Survey

In late 2019, IFFGD conducted a short survey of gastroparesis patients to study quality of life, disease severity, and patient risk assessment when considering medications and clinical trials. This survey was distributed by IFFGD to gastroparesis patients through email and social media. This survey is named the “Gastroparesis Disease Impact and Medication Risk Assessment.” During the 5 weeks the survey was open for data collection, 200 responses were received, offering valuable insight into the needs and desires of gastroparesis patients.